HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Articles by Antman, E. M. Search for Related Content PubMed Articles by Sabatine, M. S. Articles by Antman, E. M.

The thrombolysis in myocardial infarction risk score in unstable angina/non–ST-segment elevation myocardial infarction

^* TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

View larger version (18K): [in a new window]   Figure 1 Rates of all-cause mortality (D), myocardial infarction (MI) , and severe recurrent ischemia leading to urgent revascularization (UR) through 14 days among patients randomized to unfractionated heparin in Thrombolysis In Myocardial Infarction (TIMI) 11B trial, with patients stratified by the TIMI risk score. NSTEMI = non–ST-segment elevation myocardial infarction; % Popl’n = percent of overall trial population with that TIMI risk score; UA = unstable angina. Adapted from Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non–ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835–42.

View larger version (18K): [in a new window]   Figure 2 (A) Rates of all-cause mortality (D), myocardial infarction (MI), or severe recurrent ischemia leading to urgent revascularization (UR) through 14 days among all patients in Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited to very Unstable Signs and Symptoms (PRISM-PLUS) trial, with patients stratified by Thrombolysis In Myocardial Infarction (TIMI) risk score. Adapted from Morrow DA, Antman EM, Snapinn SM, McCabe CH, Theroux P, Braunwald E. An integrated clinical approach to predicting the benefit of tirofiban in non–ST-elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002;23:223–9. (B) Rates of D, MI, or re-admission for acute coronary syndrome (ACS) through 6 months among all patients in Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy (TACTICS) TIMI-18, with patients stratified by TIMI risk score. NSTEMI = non–ST-segment elevation myocardial infarction; % Popl’n = percent of overall trial population with that TIMI Risk Score; UA = unstable angina.

View larger version (27K): [in a new window]   Figure 3 Rates of all-cause mortality (D), myocardial infarction (MI), or severe recurrent ischemia leading to urgent revascularization (UR) through 14 days in the unfractionated heparin (UFH) and enoxaparin (ENOX) treatment groups in the pooled Thrombolysis In Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events (ESSENCE) trial populations, with patients stratified by TIMI risk score. NSTEMI = non–ST-segment elevation myocardial infarction; % Popl’n = percent of overall trial population with that TIMI risk score; UA = unstable angina.

View larger version (23K): [in a new window]   Figure 4 Rates of all-cause mortality (D) or myocardial infarction (MI) through 30 days in the heparin alone and tirofiban plus heparin treatment groups in Platelet Receptor inhibition for Ischemic Syndrome Management in Patients Limited to very Unstable Signs and Symptoms (PRISM-PLUS), with patients stratified by Thrombolysis In Myocardial Infarction (TIMI) trial risk score.

View larger version (26K): [in a new window]   Figure 5 Rates of all-cause mortality (D), myocardial infarction (MI), or readmission for acute coronary syndrome (ACS) through six months in the invasive (INV) and conservative (CONS) treatment strategy arms in Treat angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction (TACTICS TIMI)-18 trial, with patients stratified by TIMI risk score.